Sandoz

SANDOZ NEWSROOM (5 press releases)

Advanced Filtering & Sorting Options:

Sandoz certified “TOP Employer Asia Pacific 2019” for its exceptional employee offerings in the region

PRESS RELEASE -- 4, December 2018

Sandoz has been certified by the Top Employers Institute for its exceptional employee offerings in Asia Pacific (APAC) The annual, international research undertaken by the Top Employers Institute recognizes leading employers around the world This exclusive certification underlines Sandoz´ commitment … Read the full press release

Peter Goldschmidt succeeded Claudio Albrecht as the Chief Executive Officer of STADA Arzneimittel AG

PRESS RELEASE -- 13, September 2018

Goldschmidt: “I look forward to working with the highly experienced team at STADA and continuing the Group’s long-term growth” Supervisory Board Chairman von Au: “Goldschmidt is the right man that STADA needs to ensure the Group successfully retains its strong … Read the full press release

Sandoz announces European Commission approval for Zessly® (infliximab) for use in Europe

PRESS RELEASE -- 25, May 2018

European Commission’s (EC) approval based on comprehensive data package confirming that Zessly® matches safety, efficacy and quality of reference medicine Biosimilars such as Zessly enable earlier patient access to important medicines and positively impact healthcare systems Zessly is the third EC … Read the full press release

Novartis division Sandoz receives US FDA complete response letter regarding the Biologics Licensing Application for its proposed biosimilar rituximab

PRESS RELEASE -- 4, May 2018

Holzkirchen, Germany, 04-May-2018 — /EuropaWire/ — Sandoz, a Novartis division, announced today that the US Food and Drug Administration (FDA) has issued a complete response letter (CRL) regarding the Biologics Licensing Application (BLA) for its proposed biosimilar rituximab. Sandoz stands behind … Read the full press release

Sandoz: EMA Committee for Medicinal Products for Human Use (CHMP) adopts positive opinion for marketing authorization of infliximab

PRESS RELEASE -- 26, March 2018

Sandoz is seeking approval of biosimilar infliximab for use in all indications of its reference medicine across gastroenterology, rheumatology and dermatology Positive opinion is based on comprehensive clinical and non-clinical data that is expected to confirm that Sandoz biosimilar infliximab … Read the full press release